PT - JOURNAL ARTICLE AU - Kamal, Noreen AU - Cora, Elena A. AU - Alim, Simone AU - Goldstien, Judah AU - Volders, David AU - Aljendi, Shadi AU - Williams, Heather AU - Fok, Patrick T. AU - van der Linde, Etienne AU - Helm-Neima, Trish AU - Cashin, Renee AU - Metcalfe, Brian AU - BNSc, Julie Savoie AU - Simpkin, Wendy AU - Chisholm, Cassie AU - Hill, Michael D AU - Menon, Bijoy K. AU - Phillips, Stephen AU - the ACTEAST Collaborators TI - Improving Access and Efficiency of Acute Ischemic Stroke Treatment Across Four Canadian Provinces: A Stepped-Wedge Trial AID - 10.1101/2024.09.13.24313666 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.13.24313666 4099 - http://medrxiv.org/content/early/2024/11/01/2024.09.13.24313666.short 4100 - http://medrxiv.org/content/early/2024/11/01/2024.09.13.24313666.full AB - Background The translation of standard-of-care in acute ischemic stroke reperfusion interventions into practice is well established, but multifactorial obstacles exist in the complete adoption, which has led to inequities in access and delivery of services. The objective of this study was to improve access and efficiency of ischemic stroke treatment across four Atlantic Canadian Provinces.Methods A stepped-wedge cluster trial was conducted over 30 months with 3 clusters covering 34 sites. The trial was conducted across all 4 Atlantic Canadian provinces: Nova Scotia (NS), New Brunswick (NB), Prince Edward Island (PE), and Newfoundland and Labrador (NL). The design was quasi-randomized, with each cluster associated with one or more provinces: cluster 1 – NS; cluster 2 – NB and PE; and cluster 3 – NL. The patient population was all ischemic stroke patients across all 4 provinces. The intervention was a 6-month modified Quality Improvement Collaborative (mQIC), which was modified from the Breakthrough Series Collaborative to be half of the 1-year period and conducted virtually. The intervention consisted of assembling an interdisciplinary improvement team, 2 full-day workshops, webinars, and virtual site visits. Suggested changes included 6 process improvement strategies.Results Over the trial period, 8594 ischemic stroke patients were included, out of which 1576 patients received acute treatment. The proportion of patients that received treatment did not increase significantly with the intervention [0.4% increase for patients that received thrombolysis and/or EVT (p=0.68)]. Median door-to-needle time was reduced by 9.2 minutes with the intervention (p=0.01). Cluster 3 saw the greatest improvements in both access and efficiency.Conclusions A mQIC intervention resulted in improvement of process measures like door-to-needle time. Quality improvement initiatives may need to be longer to allow full implementation and tailored for each health system to ensure that each system sees improvement. In-person activities might be critical to ensure fidelity of the intervention.Competing Interest StatementNK: reports funding from CIHR, NSERC, Medtronic, Mitacs, NS Health, and NS Department of Education and Early Childhood Development. She has received speaker honorarium for Heart & Stroke Foundation of NB. She is part-owner of DESTINE Health Inc.Clinical TrialThe trial is registered with the ISRCTN registry (ISRCTN11109800, https://www.isrctn.com/ISRCTN11109800).Funding StatementThis study was funded by the Canadian Institutes for Health Research (CIHR) Project Grant (PJT-169124). A small grant was also received from Medtronic. The study funders had no influence in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the NS Health Research Ethics Board (REB# 1025460), Health PEI Ethics Board, Horizon Health Network Research Ethics Board (ROMEO File #: 100906 and RS#: 2020-2893), Vitalite Health Network Ethics Office (ROMEO file number: 101305), and Newfoundland and Labrador Health Research Ethics Board (Researcher Portal File #: 20210255 and Reference #: 2020.074).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data were obtain through data sharing agreements between the health system and Dalhousie University, and the data cannot be shared outside of this agreement.